APAC IPOs & Placements, Aequitas Research

Ethan Aw

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Lu DaoPei Medical Group Pre-IPO Tearsheet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Lu Daopei Medical Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lu-daopei-medical-group" target="_blank" data-smartkarma-citation="entities:36716:1" rel="noopener">Lu Daopei Medical Group (1816743D CH)</a><a href="https://www.smartkarma.com/entities/lu-daopei-medical-group-holding-limited" target="_blank" data-smartkarma-citation="entities:36709:1" rel="noopener"> </a>is looking to raise around US$400m in its upcoming Hong Kong IPO. </li>
<li>Lu DaoPei Medical Group (LDPM) is a hospital operator focusing on hematology healthcare services. As per F&amp;S, it was the largest hematology healthcare services provider in China by 2021 revenue.</li>
<li>LDPM has supported its growth through its flagship hospital. However, it is unclear whether the firm will be able to sustainably maintain profitability in the long term. </li>
</ul>



Lu Daopei Medical Group (1816743D CH) is looking to raise around US$400m in its upcoming Hong Kong IPO. 
Lu DaoPei Medical Group (LDPM) is a hospital operator focusing on hematology healthcare services. As per F&amp;S, it was the largest hematology healthcare services provider in China by 2021 revenue.
LDPM has supported its growth through its flagship hospital. However, it is unclear whether the firm will be able to sustainably maintain profitability in the long term. 


Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Shanghai United Imaging Health (688271 CH)

Lu DaoPei Medical Group Pre-IPO - Ramp up in Progress but Looks Promising